Company Description
Viridian Therapeutics, Inc. engages in discovering, developing, and commercializing treatments for serious and rare diseases.
The company’s product pipeline includes veligrotug, a monoclonal antibody targeting insulin-like growth factor-1 receptor that is in Phase 3 clinical trial for the treatment of thyroid eye disease (TED); and VRDN-003, a next generation IGF-1R monoclonal antibodies targeting IGF-1R and engineered of half-life extension technology, which is in Phase 3 clinical trial for the treatment of TED.
It also develops portfolio of engineered anti-neonatal Fc receptor inhibitors, such as VRDN-006 and VRDN-008 for autoimmune disease.
The company was formerly known as Miragen Therapeutics, Inc. and changed its name to Viridian Therapeutics, Inc. in January 2021.Viridian Therapeutics, Inc. was founded in 2010 and is headquartered in Waltham, Massachusetts.
| Country | United States |
| Founded | 2006 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 143 |
| CEO | Stephen Mahoney |
Contact Details
Address: 221 Crescent Street, Suite 401 Waltham, Massachusetts 02453 United States | |
| Phone | 617 272 4600 |
| Website | viridiantherapeutics.com |
Stock Details
| Ticker Symbol | VRDN |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001590750 |
| CUSIP Number | 92790C104 |
| ISIN Number | US92790C1045 |
| Employer ID | 47-1187261 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Stephen F. Mahoney J.D., MBA | Chief Executive Officer, President and Director |
| Seth Harmon | Chief Financial Officer |
| Thomas W. Beetham J.D., MBA | Chief Operating Officer |
| Jennifer Tousignant J.D. | Chief Legal Officer |
| Dr. Eric N. Olson Ph.D. | Co-Founder and Chairman of Scientific Advisory Board |
| Dr. Michael R. Bristow M.D., Ph.D. | Co-Founder and Member of the Scientific Advisory Board |
| Dr. Marvin H. Caruthers Ph.D. | Co-Founder and Scientific Advisory Board Member |
| Vahe Bedian Ph.D. | Co-Founder and Scientific Advisor |
| Melissa Manno | Chief Human Resources Officer |
| Anthony Casciano | Chief Commercial Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Jun 24, 2025 | 8-K | Current Report |
| May 20, 2025 | 8-K | Current Report |
| May 15, 2025 | SCHEDULE 13G | Filing |
| May 6, 2025 | 10-Q | Quarterly Report |
| May 6, 2025 | 8-K | Current Report |
| Apr 25, 2025 | ARS | Filing |
| Apr 25, 2025 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Apr 25, 2025 | DEF 14A | Other definitive proxy statements |
| Apr 11, 2025 | SCHEDULE 13G | Filing |
| Apr 7, 2025 | 8-K | Current Report |